Taken together, VOSL contained multiple anti-cancer ingredients, at least Cos and Dehy, which targeted multiple signaling pathways, at least c-Myc/p53, AKT/14-3-3 and PKA signaling pathways to exhibit synergistic anti-breast cancer efficiency, and our previous study demonstrated that VOSL and CD shows better anti-breast cancer efficacy and lower side effects than Cos or Dehy alone in vivo3. This evidence concerns the gene TP53 and breast carcinoma.